-
Je něco špatně v tomto záznamu ?
Fibrin Clot Formation under Oxidative Stress Conditions
J. Kaufmanova, J. Stikarova, A. Hlavackova, L. Chrastinova, M. Maly, J. Suttnar, JE. Dyr
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
AIIHHP: CZ.02.1.01/0.0/0.0/16_025/0007428
European Regional Development Fund
00023736
Ministerstvo Zdravotnictví Ceské Republiky
NV18-08-00149
Ministerstvo Zdravotnictví Ceské Republiky
CZ.2.16/3.1.00/24001
European Regional Development Fund
NLK
Directory of Open Access Journals
od 2012
PubMed Central
od 2012
Europe PubMed Central
od 2012
ProQuest Central
od 2012-03-01
Open Access Digital Library
od 2012-01-01
Open Access Digital Library
od 2012-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2012
PubMed
34200255
DOI
10.3390/antiox10060923
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
During coagulation, the soluble fibrinogen is converted into insoluble fibrin. Fibrinogen is a multifunctional plasma protein, which is essential for hemostasis. Various oxidative posttranslational modifications influence fibrinogen structure as well as interactions between various partners in the coagulation process. The aim was to examine the effects of oxidative stress conditions on fibrin clot formation in arterial atherothrombotic disorders. We studied the changes in in vitro fibrin network formation in three groups of patients-with acute coronary syndrome (ACS), with significant carotid artery stenosis (SCAS), and with acute ischemic stroke (AIS), as well as a control group. The level of oxidative stress marker malondialdehyde measured by LC-MS/MS was higher in SCAS and AIS patients compared with controls. Turbidic methods revealed a higher final optical density and a prolonged lysis time in the clots of these patients. Electron microscopy was used to visualize changes in the in vitro-formed fibrin network. Fibers from patients with AIS were significantly thicker in comparison with control and ACS fibers. The number of fibrin fibers in patients with AIS was significantly lower in comparison with ACS and control groups. Thus, oxidative stress-mediated changes in fibrin clot formation, structure and dissolution may affect the effectiveness of thrombolytic therapy.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21024596
- 003
- CZ-PrNML
- 005
- 20211013133850.0
- 007
- ta
- 008
- 211006s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/antiox10060923 $2 doi
- 035 __
- $a (PubMed)34200255
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Kaufmanova, Jirina $u Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technicka 5, 166 28 Prague, Czech Republic $u Department of Biochemistry, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 120 00 Prague, Czech Republic
- 245 10
- $a Fibrin Clot Formation under Oxidative Stress Conditions / $c J. Kaufmanova, J. Stikarova, A. Hlavackova, L. Chrastinova, M. Maly, J. Suttnar, JE. Dyr
- 520 9_
- $a During coagulation, the soluble fibrinogen is converted into insoluble fibrin. Fibrinogen is a multifunctional plasma protein, which is essential for hemostasis. Various oxidative posttranslational modifications influence fibrinogen structure as well as interactions between various partners in the coagulation process. The aim was to examine the effects of oxidative stress conditions on fibrin clot formation in arterial atherothrombotic disorders. We studied the changes in in vitro fibrin network formation in three groups of patients-with acute coronary syndrome (ACS), with significant carotid artery stenosis (SCAS), and with acute ischemic stroke (AIS), as well as a control group. The level of oxidative stress marker malondialdehyde measured by LC-MS/MS was higher in SCAS and AIS patients compared with controls. Turbidic methods revealed a higher final optical density and a prolonged lysis time in the clots of these patients. Electron microscopy was used to visualize changes in the in vitro-formed fibrin network. Fibers from patients with AIS were significantly thicker in comparison with control and ACS fibers. The number of fibrin fibers in patients with AIS was significantly lower in comparison with ACS and control groups. Thus, oxidative stress-mediated changes in fibrin clot formation, structure and dissolution may affect the effectiveness of thrombolytic therapy.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Stikarova, Jana $u Department of Biochemistry, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 120 00 Prague, Czech Republic
- 700 1_
- $a Hlavackova, Alzbeta $u Department of Biochemistry, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 120 00 Prague, Czech Republic
- 700 1_
- $a Chrastinova, Leona $u Department of Biochemistry, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 120 00 Prague, Czech Republic
- 700 1_
- $a Maly, Martin $u Department of Medicine, First Faculty of Medicine, Charles University in Prague and Military University Hospital, U Vojenske Nemocnice 1200, 169 02 Prague, Czech Republic
- 700 1_
- $a Suttnar, Jiri $u Department of Biochemistry, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 120 00 Prague, Czech Republic
- 700 1_
- $a Dyr, Jan Evangelista $u Department of Biochemistry, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 120 00 Prague, Czech Republic
- 773 0_
- $w MED00200130 $t Antioxidants (Basel, Switzerland) $x 2076-3921 $g Roč. 10, č. 6 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34200255 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20211006 $b ABA008
- 991 __
- $a 20211013133847 $b ABA008
- 999 __
- $a ind $b bmc $g 1708388 $s 1145093
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 10 $c 6 $e 20210607 $i 2076-3921 $m Antioxidants $n Antioxidants $x MED00200130
- GRA __
- $a AIIHHP: CZ.02.1.01/0.0/0.0/16_025/0007428 $p European Regional Development Fund
- GRA __
- $a 00023736 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a NV18-08-00149 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a CZ.2.16/3.1.00/24001 $p European Regional Development Fund
- LZP __
- $a Pubmed-20211006